Board Change • 3h
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Advisor Ilan Hayman is the most experienced director on the board, commencing their role in 2021. Independent Director Harry Jacobson was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Tillkännagivande • Apr 21
Lobe Sciences Ltd. announced that it has received CAD 0.95 million in funding On April 20, 2026, Lobe Sciences Ltd. has closed the transaction. Tillkännagivande • Apr 08
Lobe Sciences Ltd., Annual General Meeting, Jun 15, 2026 Lobe Sciences Ltd., Annual General Meeting, Jun 15, 2026. Tillkännagivande • Jan 14
Lobe Sciences Ltd Appoints Mr. Nick Karakochuk to Board of Directors Lobe Sciences Ltd. announced the appointment of Mr. Nick Karakochuk to its Board of Directors as the Company continues to build on the momentum established during fiscal 2025. Mr. Karakochuk is a corporate and securities lawyer at DuMoulin Black LLP, where his practice focuses on mergers and acquisitions, public and private financing, corporate reorganizations, and governance matters. He regularly advises public and private issuers on stock exchange requirements, securities regulatory compliance, and continuous disclosure obligations, and has extensive experience supporting companies through complex transactions and strategic growth initiatives. Tillkännagivande • Sep 10
Lobe Sciences Ltd. Appoints Mr. Marco Mastrodonato to the Company's Board of Directors Lobe Sciences Ltd. announced the appointment of Mr. Marco Mastrodonato to the Company's Board of Directors. Mr. Mastrodonato brings extensive leadership and international business development experience in the pharmaceutical and biotechnology industries. He was the former Co-Founder and Executive Director of Sinclair Pharma plc., a publicly listed pharmaceutical company on the London Stock Exchange. He founded and served as a Board Member of Metrodora Therapeutics Inc.; a U.S. biotechnology company focused on systemic inflammation and the treatment of anemia. Mr. Mastrodonato is also the Founder and CEO of BMG Pharma, where he leads the development and global commercialization of innovative hyaluronic acid-based technologies across aesthetic dermatology. ophthalmology and osteoarthritis. Tillkännagivande • Jul 29
Lobe Sciences Ltd. announced that it expects to receive CAD 0.341425 million in funding Lobe Sciences Ltd announced a non brokered private placement to issue 8,535,625 common shares at an issue price of CAD 0.04 for the proceeds of CAD 341,425 on July 29, 2025. All securities to be issued pursuant to the offering will be subject to a statutory four-month-and-one-day hold period. Tillkännagivande • Jan 15
Lobe Sciences Ltd., Annual General Meeting, Mar 20, 2025 Lobe Sciences Ltd., Annual General Meeting, Mar 20, 2025. Tillkännagivande • Nov 19
Lobe Sciences Ltd. and Alera Pharma, Inc. Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™ Lobe Sciences Ltd. and Alera Pharma Inc. announced that a second patent allowance for Conjugated Psilocin™ has been received. The patent application is entitled Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof. This application contains claims covering compositions comprising a psilocin mucate salt or conjugate and methods for their production and use in conditions treatable with psilocin. New Risk • Sep 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 117% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (141% average daily change). Negative equity (-CA$1.1m). Earnings have declined by 6.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (117% increase in shares outstanding). Revenue is less than US$1m (CA$977k revenue, or US$720k). Market cap is less than US$10m (€2.30m market cap, or US$2.53m). Tillkännagivande • Aug 16
Lobe Sciences, Ltd Announces Management Appointments to Alera Pharma, Inc Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") announced that is has formed a wholly owned U.S. subsidiary named Alera Pharma Inc. (Alera). Alera will be assigned the intellectual property rights focused on the Company’s neurological assets and its new chemical entity Psilocin Mucate. Mr. Rick Goulburn has been appointed as the Chief Executive Officer of Alera. Dr. Fred D. Sancilio will be Chairman of its Board of Directors and be joined on the board by Dr. Harry Jacobson, Mr. Wesley Ramjeet and Mr. Goulburn. Alera will be the operating company within the Lobe Sciences group focused on neurology and will join Altemia, LLC as the second operating subsidiary of Lobe Sciences. It is expected that the Company’s Australian subsidiary, Lobe Sciences Australia Pty Ltd., will become a subsidiary of Alera. Mr. Ilan Hayman will become a member of the executive management team of Alera. Tillkännagivande • Jun 01
Lobe Sciences Ltd. Announces Frederick D. Sancilio Ph.D. to Join Board of Directors Lobe Sciences Ltd. announced that Frederick D. Sancilio Ph.D. has agreed to join its Board of Directors. Dr. Sancilio brings over four decades of successful experience in pharmaceutical sciences and biopharmaceutical research, further strengthening Lobe Sciences' commitment to pioneering advancements in mental health and wellness. Dr. Sancilio completed his B.S., M.S., and Ph.D. in Physical and Analytical Chemistry at Rutgers, The State University of New Jersey. His career has been marked by significant achievements, including founding aaiPharma Inc., where he led the company to become the world's dosage form development company with over 1,000 US FDA and 500 European drug approvals. Dr. Sancilio has a proven track record of driving growth and innovation, having founded multiple successful pharmaceutical companies and contributed to the biopharmaceutical industry's development in North Carolina. As a serial entrepreneur Dr. Sancilio is largely responsible for helping to define the modern Contract Research and Development Organization marketplace with the founding of aaiPharma Inc. which focused on providing drug product development services to both entrepreneurial and established pharmaceutical companies. The company became a NASDAQ publicly traded company in 1996 and grew to a market capitalization of nearly $1BB by 2001. Dr. Sancilio retired from aaiPharma in June 2002. The company was reorganized in 2005, privatized and renamed Alcami Inc., and continues to dominate its business segment. Following his retirement as CEO of aaiPharma in 2002, Dr. Sancilio established a family office in Jupiter, Florida and affiliated with several investment and merchant banks in South Florida including Comvest Partners and the Noble Capital Markets. In 2007, he founded Sancilio & Company Inc. (SCI), a specialty pharmaceutical company located in Palm Beach County, Florida. SCI’s primary focus was to develop drug products for diseases with unmet medical needs. The Company’s 150,000 square foot facility in Riviera Beach, Fl was approved as a drug manufacturing site by the US FDA in 2017 and received its first prescription drug approval in that facility in early 2018 making it the first US FDA approval of a drug product in Palm Beach County in over 2 decades. Facilities, products and intellectual property were acquired in early 2018 and are now operated by Procaps Group SA, a NASDAQ listed Company. In early January 2018, Dr. Sancilio and his wife Carolyn Sancilio founded Clearway Global Inc., a consulting and product development company that is wholly owned by Sancilio & Company, located in Stuart, Fl. He continues to do research and development work in sickle cell disease, broad spectrum anti-viral drugs and neurological disorders including Alzheimer’s Disease, substance abuse and addiction. He is also involved in guiding the development of several new drug candidates for Clearway Global’s international client companies where he serves in a variety of positions. In July 2019, Dr. Sancilio accepted a position as a Research Professor and Managing Director, Translational Development & Commercialization in the Division of Research at Florida Atlantic University, Boca Raton, Fl and continues as a Research Professor in the Department of Chemistry and Biochemistry. Tillkännagivande • May 31
Harry Jacobson to Join the Board of Directors of Lobe Sciences Ltd Lobe Sciences Ltd. announced that Dr. Harry Jacobson has agreed to join its Board of Directors in the coming months. Dr. Jacobson brings over three decades of distinguished experience in healthcare, biotechnology, and medical innovation. As a serial entrepreneur, executive and visionary leader, his extensive knowledge and strategic insights will be invaluable to Lobe Sciences as the company continues to pioneer treatments and expand its footprint in the development of transformative medicines for orphan and rare diseases. Board certified in Internal Medicine and Nephrology, Dr. Jacobson joined Vanderbilt Medical Faculty in 1985 as Professor of Medicine and Director of the Division of Nephrology. After developing one of the nation’s premier nephrology divisions, Dr. Jacobson was named Vice Chancellor for Health Affairs and CEO of the Vanderbilt University Medical Center (VUMC). As Vice Chancellor for Health Affairs, Dr. Jacobson’s 12-year tenure saw the VUMC budget expand from $750M to $2.5B, all the while delivering superior care. Vanderbilt’s federally funded research moved from 24th to top 10 in the country and more than $1B of newly constructed facilities were opened. Among these projects are the Monroe Carell Children’s Hospital and Vanderbilt Health at 100 Oaks. During the course of his career, Dr. Jacobson has been a successful investor and entrepreneur, having founded or co-founded several companies, including Contact Software, the developer of the software program ACT which helped launch the CRM software category; Renal Care Group; Cardiovascular Care Group; Informatics Corporation of America; CeloNova Biosciences, Ambulatory Services of America; MindCare Solutions; Innovative Renal Care; MedLogic, and For Better Health (4BH). He has served on the boards of three New York Stock Exchange companies including Merck, Kinetic Concepts, and Renal Care Group. Currently, Dr. Jacobson serves on the Board of Directors of several healthcare companies from the original MedCare portfolio. In 2013, Dr. Jacobson served Belmont’s Jack C. Massey Graduate School of Business as its Distinguished Healthcare Executive-in-Residence and was Chairman of the McWhorter Society from 2014 to 2017. Tillkännagivande • May 17
Lobe Sciences Ltd., Annual General Meeting, Jul 22, 2024 Lobe Sciences Ltd., Annual General Meeting, Jul 22, 2024. Location: british columbia, vancouver Canada New Risk • May 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$225k free cash flow). Share price has been highly volatile over the past 3 months (273% average daily change). Negative equity (-CA$1.2m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (CA$977k revenue, or US$714k). Market cap is less than US$10m (€2.24m market cap, or US$2.41m). Minor Risk Shareholders have been diluted in the past year (6.2% increase in shares outstanding). New Risk • Mar 29
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 93% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.7m free cash flow). Share price has been highly volatile over the past 3 months (152% average daily change). Negative equity (-CA$160k). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Revenue is less than US$1m (CA$841k revenue, or US$621k). Market cap is less than US$10m (€2.03m market cap, or US$2.19m). New Risk • Feb 16
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$160k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.7m free cash flow). Share price has been highly volatile over the past 3 months (59% average daily change). Negative equity (-CA$160k). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (102% increase in shares outstanding). Revenue is less than US$1m (CA$841k revenue, or US$624k). Market cap is less than US$10m (€2.14m market cap, or US$2.30m). Tillkännagivande • Dec 07
Lobe Sciences Ltd. Provides Update on L-130 Clinical Program Lobe Sciences Ltd. provided an update from the Company's lead clinical program, L-130, a proprietary stabilized psilocin conjjugate drug candidate. The Phase 1 study (NCT06035900) was an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmacokinetic parameters of L-130 after a single oral dose. All subjects were evaluated for impacts on cognition and anxiolytic effects on day 1, 7 and 28. All subjects were dosed with no significant adverse events. The study confirmed the improved pharmacokinetics of L-130 delivered as a shelf-stable, capsule over its active prodrug, psilocybin. The mean maximum plasma concentration (Cmax) for L-130 was significantly higher than expected, demonstrating superior bioavailability compared to published literature of psilocybin. Additionally, time to achieve the maximum plasma concentration (Tmax) was lower for L-130 due to elimination of first-pass metabolism and immediate absorption in the gut. Full results are expected to be published in peer reviewed journals in the first half of 2024. Collectively, the superior pharmacokinetics of L- 130 offers significant therapeutic advantages over other psilocybin formulations as psilocybin itself is not biologically active in humans and must be converted into psilocin via dephosphorylation in the gut. By eliminating this first pass metabolism, industry experts believe the direct administration of psilocin may offer therapeutic benefits such as faster onset time, improved dosing consistency, increased bioavailability and importantly, the potential for reduced side effects. Tillkännagivande • Sep 19
Lobe Sciences Ltd. Appoints Mathew Lee as Chief Financial Officer Lobe Sciences Ltd. that Mathew Lee will join the organization as Chief Financial Officer, effective September 18, 2023. Mathew has over 15 years of experience as a finance executive. Mathew currently serves as president of Manning Lee Management Ltd., a management consulting firm providing CFO services to publicly traded companies. Mathew specializes in providing M&A, accounting, management, securities regulatory compliance, and corporate secretarial services to companies listed on the TSX-V, CSE, and OTC. Mathew is a CPA Charterholder and earned a B.Comm from the University of British Columbia. Tillkännagivande • Jun 28
Lobe Sciences Ltd. Initiates Phase 1 Clinical Trial of L-130 Lobe Sciences Ltd. announced the initiation of a Phase 1, pharmacokinetic clinical study of L-130, a proprietary stabilized psilocin analogue drug candidate in healthy volunteers. The first-in-man, open-label study, conducted in Jordan under the authority of the Jordan Food and Drug Administration, will help determine the dose range of L-130 for a planned Phase 2 trial targeting the treatment of chronic cluster headaches (CCH), the most predominant headache disorder within the group of trigeminal autonomic cephalgias (TACs). The Phase 1 study, conducted in compliance with the GCP and GLP regulatory requirements of the Declaration of Helsinki and the US FDA Guidelines for Bioavailability & Bioequivalence Studies, is an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmacokinetic parameters of L-130 after a single oral dose. All subjects will be evaluated for impacts on cognition and anxiolytic effects on day 1, 7 and 28. To date, all subjects have been dosed with no significant adverse events. Full completion of the study is expected in Third Quarter 2023 and results will be used to determine L-130 dose levels for a planned Phase 2a study in chronic cluster headaches. Often said to be the most painful of all headaches, cluster headaches are a primary headache disorder and the most common of the group of headache disorders called trigeminal autonomic cephalalgias. The term cluster headaches comes from the fact that these attacks occur in groups, or "clusters." During a cluster cycle, brief, exceptionally severe headache attacks recur between 1-8 times per day. Cluster cycles can last for weeks or months and are usually separated by remission periods, or periods of headache freedom, which usually last months or years. People who experience chronic cluster headache have no remission periods, or the remissions last less than a month at a time. Tillkännagivande • Jun 08
Lobe Sciences Appoints Baxter Phillips as Chief Operating Officer Lobe Sciences Ltd. announced the appointment of Baxter Phillips III, MBA, to the newly created position of Chief Operating Officer (COO) effective immediately. The position was created to provide additional executive leadership as Lobe Sciences continues its strategic transition to a diversified, fully integrated biopharmaceutical company preparing to launch its first commercial product, Altemia™, a medical food designed for patients with sickle cell anemia. Mr. Phillips will also serve as President, Altemia and Company, LLC, a Lobe Sciences wholly owned subsidiary focused on treatments and support for patients with sickle cell anemia. Phillips will report directly to Chairman and Chief Executive Officer Philip J. Young. In October of 2022, Mr. Phillips was appointed to Lobe Sciences' Board of Directors, where he will also continue to serve the Company. For the past 10 years of his 25 year career, Baxter has served as an executive officer, including CEO, of several multi-national biopharmaceutical companies including Cambridge Allergy (UK), Neurogastrx (US) and Armata Pharma (AmpliPhi, multi-national). Mr. Phillips has a successful history of acquiring and launching commercial products, leading multiple public and private financing campaigns, establishing cGMP manufacturing, and licensing product portfolios of commercial and development-stage programs. Mr. Phillips began his career as a research scientist with Insmed (INSM) where for ten years he held a range of leadership positions in research, licensing, finance, investor relations, and sales and marketing. He earned his MBA from the College of William and Mary and his Bachelor of Science in Biology from Hampden-Sydney College. Board Change • Nov 16
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Member of Scientific Advisory Board Mark Geyer is the most experienced director on the board, commencing their role in 2020. Independent Director Mike Petter was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Jun 14
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. Executive Chairman Jonathan Gilbert is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 